Rare Cancers, Common Need

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cancer immunotherapy, and in particular immune checkpoint blockade, has transformed oncology with the potential for durable responses even in patients with metastatic disease. To date, regulatory approvals and clinical trials have focused on the study of these agents in relatively more common tumor types, such as melanoma, non-small cell lung cancer, bladder cancer, and kidney cancer, amongst others.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Sandip Patel
S1609 DART clinical study chair; Assistant professor of medicine, UC San Diego Cancer Center;
Assistant director, Clinical Trials Office, Moores Cancer Center; Investigator, SWOG early therapeutics and rare cancers committee
Young Kwang Chae
S1609 DART translational medicine study chair; assistant professor, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine; Co-director, Developmental Therapeutics, Lurie Cancer Center; Vice chair, SWOG early therapeutics and rare cancers committee
Razelle Kurzrock
S1609 DART senior study chair; Senior deputy center director, Moores Cancer Center; Chief, Division of Hematology and Oncology, UC San Diego; Chair, SWOG early therapeutics and rare cancers committee

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 
Sandip Patel
S1609 DART clinical study chair; Assistant professor of medicine, UC San Diego Cancer Center;
Assistant director, Clinical Trials Office, Moores Cancer Center; Investigator, SWOG early therapeutics and rare cancers committee
Young Kwang Chae
S1609 DART translational medicine study chair; assistant professor, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine; Co-director, Developmental Therapeutics, Lurie Cancer Center; Vice chair, SWOG early therapeutics and rare cancers committee
Razelle Kurzrock
S1609 DART senior study chair; Senior deputy center director, Moores Cancer Center; Chief, Division of Hematology and Oncology, UC San Diego; Chair, SWOG early therapeutics and rare cancers committee

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login